- ￥1560 - 13920
- TargetMol
- T41016
- 2026年07月07日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- CAS号：
886214-18-2
- 规格：
1mLx10mM(inDMSO)/2mg/5mg/25mg/50mg/100mg
| 规格： | 1mLx10mM(inDMSO) | 产品价格： | ￥2864.0 |
|---|---|---|---|
| 规格： | 2mg | 产品价格： | ￥1560.0 |
| 规格： | 5mg | 产品价格： | ￥2312.0 |
| 规格： | 25mg | 产品价格： | ￥7632.0 |
| 规格： | 50mg | 产品价格： | ￥9920.0 |
| 规格： | 100mg | 产品价格： | ￥13920.0 |
Product Introduction
Bioactivity
| 名称 | Vercirnon sodium |
| 描述 | Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent CCR9 antagonist. It effectively inhibits CCR9-mediated calcium mobilization and chemotaxis in Molt-4 cells, exhibiting IC50 values of 5.4 nM and 3.4 nM, respectively. Demonstrating high selectivity, Vercirnon sodium does not significantly affect CCR1-12 or CX3CR1-7, with IC50 values exceeding 10 µM for these receptors. Additionally, it inhibits CCL25-directed chemotaxis equally well in both CCR9 splice variants, CCR9A and CCR9B, with IC50 values of 2.8 nM and 2.6 nM, respectively. |
| 体外活性 | Vercirnon (GSK-1605786) sodium inhibits chemotaxis of primary CCR9-expressing cells to CCL25 with an IC 50 of 6.8 nM. Vercirnon sodium inhibits CCL25-Induced Chemotaxis of retinoic acid (RA)-Cultured Human T Cells. Vercirnon sodium inhibits RA-cultured cell CCL25-medidated chemotaxis in 100% human AB serum resulted in an IC 50 of 141 nM. Vercirnon sodium is a potent inhibitor of CCL25-induced mouse and rat thymocyte chemotaxis with IC 50 values of 6.9 nM and 1.3 nM, respectively[1]. |
| 体内活性 | Vercirnon (GSK1605786A) sodium (10, 50 mg/kg; s.c.; twice per day; starting at 2 weeks of age until 12 weeks of age) ameliorates the severity of intestinal inflammation in the TNFΔARE mouse model[1]. Animal Model: C57BL/6 mice (TNFΔARE Mouse Model of Terminal Ileitis)[1]Dosage: 10, 50 mg/kg Administration: Subcutaneous; twice per day; starting at 2 weeks of age until 12 weeks of age Result: Resulted in complete protection from the severe inflammation associated with TNF- overexpression at 50 mg/kg. A similar protective effect was also noted with a lower dose. |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 关键字 | Vercirnon sodium |
| 相关产品 | BMS-817399 | Maraviroc | Pirfenidone | Ancriviroc | AZD2098 | Vercirnon | PNU-177864 | CCR2 antagonist 5 | Artemotil | MLN-3897 TFA | INCB-9471 | CCR6 antagonist 1 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验介绍显示Ca2+ ATPase的钙―钴法。 三磷酸腺苷酶钙―钴法类似碱性磷酸酶的钙―钴法，但底物改用三磷酸腺苷钠盐，最适pH 9．4，对ATP酶型Mg2+ 具有抑制作用。 1．孵育液配制 0．1mol/L巴比妥钠(pH 9．4) 2．0ml 三磷酸腺苷二钠盐 30mg 蒸馏水 1．0ml 0．
一个DNA碱基对（钠盐）的平均分子量 = 650 道尔顿 1.0 A260 unit ds DNA = 50 µg/ml = 0.15 mM (in nucleotides) 1.0 A260 unit ss DNA = 33 µg/ml = 0.10 mM (in nucleotides) 1.0 A260 unit ss RNA = 40 µg/ml = 0.11 mM (in nucleotides) 双链DNA分子的分子量(道尔顿) = 碱基对数目×650
管病死亡率 （四）讨论题 1．选择这类糖尿病人作研究，在实验结论的适用范围上会有什么影响？ 2．临床试验是否一定要双盲？为什么？双盲试验包括哪些内容？ 3．设立一个安慰剂治疗组是否合乎医德要求？ 4．假如不包含安慰剂治疗组会失去哪些结论？ 5．为什么说随机化是主要的，怎样去实现随机化？ 6．这次临床实验有哪些主要特点？ 二、无钠盐饮食治疗轻度高血压的随机对照实验 113例
技术资料暂无技术资料 索取技术资料
